• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Coya Therapeutics, Inc. - Common Stock (NQ:COYA)

    6.365 +0.065 (+1.03%)
    Streaming Delayed Price Updated: 1:30 PM EDT, Oct 17, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 30,047
    Open 6.283
    Bid (Size) 6.310 (1)
    Ask (Size) 6.460 (2)
    Prev. Close 6.300
    Today's Range 6.062 - 6.435
    52wk Range 4.650 - 10.24
    Shares Outstanding 9,947,915
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function
    From Coya Therapeutics, Inc.
    Via Business Wire
    EXCLUSIVE: Coya Therapeutics Investigational Combination Therapy With GLP-1 Shows Potential For Alzheimer's Disease
    Coya's COYA 303 showed strong immune modulation and reduced inflammation in the brain, supporting its development for neurodegenerative diseases like Alzheimer's. 
    Via Benzinga

    Performance

    YTD
    +11.5%
    +11.5%
    1 Month
    +12.3%
    +12.3%
    3 Month
    +6.8%
    +6.8%
    6 Month
    +21.0%
    +21.0%
    1 Year
    -20.3%
    -20.3%

    More News

    Read More
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    What's Going On With Coya Therapeutics Stock?
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson’s Disease
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025
    From Coya Therapeutics, Inc.
    Via Business Wire
    Updated Lineup Announced for iAccess Alpha's Virtual Summer Investment Conference, June 24–25, 2025
    Via ACCESS Newswire
    iAccess Alpha's Virtual Best Ideas Summer Investment Conference June 24-25, 2025
    Via ACCESS Newswire
    Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025
    From Coya Therapeutics, Inc.
    Via Business Wire
    Why Meta Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Coya Therapeutics Announce Positive Interim Result from Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia
    Via Get News
    Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)
    From Coya Therapeutics, Inc.
    Via Business Wire
    Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results
    From Coya Therapeutics, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer’s Disease Using GLP-1 Agonists and Combinations
    From Coya Therapeutics, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is Coya Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Coya Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Coya Therapeutics, Inc. - Common Stock trade on?
    Coya Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Coya Therapeutics, Inc. - Common Stock?
    The ticker symbol for Coya Therapeutics, Inc. - Common Stock is COYA on the Nasdaq Stock Market
    What is the current price of Coya Therapeutics, Inc. - Common Stock?
    The current price of Coya Therapeutics, Inc. - Common Stock is 6.365
    When was Coya Therapeutics, Inc. - Common Stock last traded?
    The last trade of Coya Therapeutics, Inc. - Common Stock was at 10/17/25 01:30 PM ET
    What is the market capitalization of Coya Therapeutics, Inc. - Common Stock?
    The market capitalization of Coya Therapeutics, Inc. - Common Stock is 63.32M
    How many shares of Coya Therapeutics, Inc. - Common Stock are outstanding?
    Coya Therapeutics, Inc. - Common Stock has 63M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.